Innodata Inc vs NeoGenomics Inc. Common Stock — how do they compare? Innodata Inc trades at $51.81 (market cap $2.01B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.14B). The key difference: Innodata Inc and NeoGenomics Inc. Common Stock are close in size by market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 20 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| INOD | NEO | |
|---|---|---|
Market Cap | $2.01B | $2.14B |
Volume | 722,859 | 2,228,400 |
Sector | Technology | Health |
52-Week High | $121.50 | $19.91 |
52-Week Low | $34.45 | $7.19 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $1.76B | $2.44B |
Signals from Pluang's Aura AI — not financial advice
INOD is trading at $58.38, down 2.55% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 42.71% gross margins and 37.74% ROE, while expanding into motion-capture AI labs and agentic reinforcement learning. Analyst consensus remains positive with 66.7% buy ratings, though valuation metrics appear elevated with a P/E of 45.26.
The outlook balances strong AI services growth against premium valuation concerns. Investment opportunity lies in continued execution on AI data engineering contracts with major tech companies, while risks include customer concentration and competitive pressures in the rapidly evolving AI infrastructure market.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →